Evidence map›Paper›PMID 41591987›Full record

Observational studyEuropean heart journal. Quality of care & clinical outcomes2026

Validation of the European SCORE2 algorithm in one European and one Latin-American cohort studies with contrasting populations.

Ko Ko Maung, Eirini Trichia, Henrique Barros, Vlada Hanchar, Jesus Alegre-Díaz, Jaime Berumen, Pablo Kuri-Morales, Roberto Tapia-Conyer, Louisa Gnatiuc Friedrichs, Pedro Marques-Vidal

Abstract readObservational StudyValidation Study
In one paragraph

Observational study in European heart journal. Quality of care & clinical outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ko Ko MaungDepartment of Medicine, Internal Medicine, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-3506-3701
Eirini TrichiaClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0002-7655-5905
Henrique BarrosEpidemiology Research Unit (EPIUnit), Instituto de Saúde Pública da Universidade do Porto (ISPUP), Porto, Portugal.ORCID 0000-0003-4699-6571
Vlada HancharEpidemiology Research Unit (EPIUnit), Instituto de Saúde Pública da Universidade do Porto (ISPUP), Porto, Portugal.ORCID 0009-0001-6698-1257
Jesus Alegre-DíazExperimental Research Unit from the Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Jaime BerumenExperimental Research Unit from the Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.ORCID 0000-0001-6707-3317
Pablo Kuri-MoralesEscuela de Medicina y Ciencias de la Salud, Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Mexico.ORCID 0000-0002-0704-9507
Roberto Tapia-ConyerExperimental Research Unit from the Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Louisa Gnatiuc FriedrichsClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0002-0641-2220
Pedro Marques-VidalDepartment of Medicine, Internal Medicine, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-4548-8500

Funding

Swiss National Science Foundation 320030_207687
6 · The paper itself

Abstract

aimsSCORE2 estimates the 10-year risk of developing non-fatal and fatal cardiovascular disease (CVD), and it was designed for mostly Europeans. However, its transferability to non-European populations has not been extensively studied. The aim of this study was to evaluate the performance of the SCORE2 in ethnically and socioeconomically diverse populations, including those outside of Europe. METHODS AND

resultsWe leveraged cohort studies from Mexico (N = 95,660, mean age 52.4 years, 32.6% men, mean follow-up 9.7 years), and Portugal (N = 1,216, 52.9 years, 36.9% men, 8.8 years follow-up). SCORE2 has differentially classified frequency of CVD events across levels of risk severity, ranging from 0.7-1.0% CVD events among those with low-moderate risk-profiles, vs. 6.6-9.0% among those with high risk-profiles, respectively. The area under the receiver operating curve (AROC) was 0.762 in Mexico and 0.718 in Portugal. Sensitivities (95% CI) were 85.7 (84.2-87.2) and 95.0 (86.1-99.0), and specificities were 42.8 (42.5-43.1) and 24.3 (21.9-26.9) for Mexico and Portugal, respectively. In all cases, the positive predictive values were below 7%, whereas the negative predictive values were all above 98%. Harrell's C were 0.717 and 0.692, and Brier's scores were 0.022 and 0.052 for Mexico and Portugal, respectively. In Mexico, SCORE2 showed good calibration, with a slight overestimation in the higher-risk categories. In Portugal, overestimation in higher-risk categories was more substantial.

conclusionSCORE2 estimates modest to acceptable performance for predicting the 10-year CVD in Mexicans but performed less favourably in the Portuguese cohort, indicating a need for recalibration.

Indexed as

AlgorithmsCardiovascular DiseasesEuropean PeopleNorth American PeopleCohort StudiesFemaleHumansMaleMexicoMiddle AgedPortugalRisk AssessmentMexicoPortugalPrimary preventionRisk assessmentScoresValidation

Identifiers

PMID41591987
PMCPMC13457936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.